343
Participants
Start Date
October 20, 2014
Primary Completion Date
December 6, 2019
Study Completion Date
December 14, 2020
SD-809
SD-809 will be administered per dose and schedule specified in the arm.
Placebo
Placebo matching to SD-809 will be administered per schedule specified in the arm.
Teva Investigational Site 538, Budapest
Teva Investigational Site 541, Budapest
Teva Investigational Site 545, Kalocsa
Teva Investigational Site 539, Doba
Teva Investigational Site 530, Prague
Teva Investigational Site 156, Washington D.C.
Teva Investigational Site 101, Glen Burnie
Teva Investigational Site 154, Baltimore
Teva Investigational Site 146, Raleigh
Teva Investigational Site 133, Charleston
Teva Investigational Site 165, Decatur
Teva Investigational Site 155, Augusta
Teva Investigational Site 150, Lake City
Teva Investigational Site 117, Gainesville
Teva Investigational Site 112, Orlando
Teva Investigational Site 153, Miami
Teva Investigational Site 162, Miami
Teva Investigational Site 157, Boca Raton
Teva Investigational Site 144, Port Charlotte
Teva Investigational Site 145, Tuscaloosa
Teva Investigational Site 149, Memphis
Teva Investigational Site 114, Garfield Heights
Teva Investigational Site 166, Waukesha
Teva Investigational Site 504, Mainz
Teva Investigational Site 131, Chicago
Teva Investigational Site 175, St Louis
Teva Investigational Site 161, St Louis
Teva Investigational Site 118, Creve Coeur
Teva Investigational Site 142, Kansas City
Teva Investigational Site 151, Fort Worth
Teva Investigational Site 129, Englewood
Teva Investigational Site 115, Salt Lake City
Teva Investigational Site 141, Salt Lake City
Teva Investigational Site 128, Albuquerque
Teva Investigational Site 121, Los Angeles
Teva Investigational Site 174, Norwalk
Teva Investigational Site 123, Glendale
Teva Investigational Site 130, Oceanside
Teva Investigational Site 110, San Diego
Teva Investigational Site 176, Loma Linda
Teva Investigational Site 104, San Bernardino
Teva Investigational Site 160, Irvine
Teva Investigational Site 107, Anaheim
Teva Investigational Site 108, Anaheim
Teva Investigational Site 102, Orange
Teva Investigational Site 169, San Rafael
Teva Investigational Site 167, Richland
Teva Investigational Site 556, Hostivice
Teva Investigational Site 540, Balassagyarmat
Teva Investigational Site 147, Los Angeles
Teva Investigational Site 139, New Haven
Teva Investigational Site 178, Lincoln
Teva Investigational Site 559, Havířov
Teva Investigational Site 535, Litoměřice
Teva Investigational Site 557, Pilsen
Teva Investigational Site 533, Prague
Teva Investigational Site 502, Gera
Teva Investigational Site 546, Győr
Teva Investigational Site 514, Bełchatów
Teva Investigational Site 554, Bialystok
Teva Investigational Site 510, Bydgoszcz
Teva Investigational Site 519, Bydgoszcz
Teva Investigational Site 536, Bydgoszcz
Teva Investigational Site 523, Chełmno
Teva Investigational Site 517, Choroszcz
Teva Investigational Site 513, Gdansk
Teva Investigational Site 512, Katowice
Teva Investigational Site 552, Katowice
Teva Investigational Site 520, Krakow
Teva Investigational Site 509, Krakow
Teva Investigational Site 508, Lodz
Teva Investigational Site 511, Lublin
Teva Investigational Site 524, Lublin
Teva Investigational Site 549, Olsztyn
Teva Investigational Site 522, Torun
Teva Investigational Site 550, Warsaw
Teva Investigational Site 516, Wroclaw
Teva Investigational Site 529, Bratislava
Teva Investigational Site 525, Domaša
Teva Investigational Site 527, Košice
Teva Investigational Site 528, Rimavská Sobota
Teva Investigational Site 526, Rožňava
Lead Sponsor
Auspex Pharmaceuticals, Inc.
INDUSTRY